Home › Amyloidosis › Ohio › Cleveland
Amyloidosis clinical trials in Cleveland, OH
5 studies for Amyloidosis are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
RecruitingPhase 3
- Clinical Trial Site, Cleveland
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
RecruitingObservational study
- Cleveland Clinic, Cleveland
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- Cleveland Clinic, Cleveland
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
- Research Site, Cleveland
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
- Cleveland Clinic, Cleveland
About Amyloidosis
Amyloidosis is a rare condition that can affect different organs of the body. Find out about amyloidosis treatment and symptoms.
More about Amyloidosis on MedlinePlus
Amyloidosis trials in other cities
- Boston, MA11 studies
- New York City, NY10 studies
- Rochester, MN10 studies
- Dallas, TX9 studies
- Philadelphia, PA7 studies
- Durham, NC6 studies
- St. Louis, MO6 studies
- Baltimore, MD6 studies
- Portland, OR6 studies
- Houston, TX6 studies
- Chicago, IL5 studies
- Washington, DC5 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer44 studies
- Cancer (all types)37 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer28 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer21 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.